Lupus & antiphospholipid syndrome
The effectiveness of telitacicept in patients with systemic lupus erythematosus: A retrospective, real-world study
Authors' conclusion
Telitacicept exhibited a highly effective and favorable safety in patients with SLE, with improved renal and hematological manifestations and facilitated a reduction in glucocorticoid medication usage.
Study context
- Population
- Patients with Systemic Lupus Erythematosus (SLE) at Tangdu Hospital, January 2022 to January 202360 completed 24 wk
- Participants
- 61 patients
- Exposure
- Telitacicept 80 mg or 160 mg; 80 mg vs 160 mg dose
- Outcome
- SRI-4 response
Methodological detailsreal-world, single-centre
- Real-world
- Single-centre
Main finding
As reported in the abstract
SRI-4 response rate (all patients) · 4, 12, 24 and 52 weeks
SRI-4 response at 4 weeks
52.5%
SRI-4 response at 12 weeks
67.2%
SRI-4 response at 24 weeks
75.4%
SRI-4 response at 52 weeks
80.0%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| SRI-4 response rate, 80 mg vs 160 mg · all time pointsNo statistically significant differences | all p > 0.05 |
Changes from baseline · 52 weeks
- SELENA-SLEDAI score decreased from baseline
- P < 0.001
- Complement 3 and 4 levels increased
- P = 0.001
- Albumin levels increased
- P = 0.004
- Overall change in GC dosage
- P < 0.001
- All showing significant changes over time
- P < 0.001
Safety
Infection · during the study
- Patients with infection
- 3 (4.9%)
Injection-site allergy · during the study
- Patients with injection-site allergy
- 1 (1.6%)
Original publication
The effectiveness of telitacicept in patients with systemic lupus erythematosus: A retrospective, real-world study. Lupus. Published 23 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →